sur Bb Biotech (isin : CH0038389992)
BB Biotech AG Reports Strong Interim Financial Results
BB Biotech AG has released its interim report for the period ending September 30, 2026. The company recorded a notable net profit of CHF 605 million for the first nine months, a significant increase from CHF 106 million in the same period the previous year. However, the third-quarter profit dropped to CHF 175 million compared to CHF 448 million in the third quarter of the previous year.
The reported profits are indicative of the performance of the stocks held in BB Biotech AG's portfolio. The company focuses its investments primarily on innovative drug developers based in the US and Western Europe.
BB Biotech AG, one of the largest investors in biotechnology, continues to build its investment strategies through its experienced Board of Directors and Bellevue Asset Management AG's investment team.
R. E.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Bb Biotech